Back to Authors

Mansfield, Aaron S.

https://orcid.org/0000-0002-9483-6903

Mayo Clinic

Mayo Clinic

Citations 186

Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer
Mansfield, Aaron S. , Sukov, William R. , Eckel‐Passow, Jeanette E. , Sakai, Yuta , Walsh, Frank J., Lonzo, Melissa L., Wiktor, Anne E., Jenkins, Robert B. , Doǧan, Ahmet , Mansfield, Aaron S

American Journal of Clinical Pathology | January 25, 2013 | Volume: 139 | Issue: 2 | Pages: 144-150

10.1309/ajcp13gjaojayjmw Get It

Abstract The determination of HER2 amplification is critical to selecting appropriate patients for HER2 targeted therapy in breast cancer. Dual in situ hybridization (DISH), an alternative to fluorescence in situ hybridization (FISH) and immunohistochemistry, is now available. To compare the FISH and DISH methods, we tested 251 samples enriched for common or difficult-to-assess HER2 anomalies. Seven samples failed DISH testing. There was a 64% (156/244) concordance between FISH and DISH by anomaly (κ = 0.58, 95% confidence interval, 0.51-0.65; P < .0001) and an 83% (203/244) concordance by amplification status (κ = 0.58; 95% confidence interval, 0.47-0.69; P < .0001). DISH resulted in lower estimates of HER2/ centromere 17 ratios than FISH, and many cases that were equivocal with FISH were normal with DISH. DISH did not detect any case with coamplification of HER2 and centromere 17. Using a cohort of difficult specimens, we observed less than 95% concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio.
Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes
Mansfield, Aaron S. , Nevala, Wendy K. , Dronca, Roxana , Leontovich, Alexey A. , Shuster, Lynne T., Markovic, S. N. , Mansfield, Aaron S

Clinical and Experimental Immunology | July 23, 2012 | Volume: 170 | Issue: 2 | Pages: 186-193

10.1111/j.1365-2249.2012.04644.x Get It

SummaryWe have observed T helper type 2 (Th2) polarization of systemic immunity in patients with metastatic malignant melanoma. We hypothesized that similar changes in systemic immunity occur with ageing and may be permissive for the development of melanoma. We analysed the peripheral blood of 389 healthy blood donors. All subjects were profiled for peripheral blood T cell and B cell subsets, and 58 of these subjects were profiled for antigen-specific cytotoxic T cell subsets [cytomegalovirus (CMV), influenza and melanoma antigen recognized by T cells 1 (MART-1)]. Ninety-five separate healthy subjects underwent profiling of 42 plasma cytokines. Ageing was associated positively with CD4+CD294+ Th2 cells, and associated negatively with CD3+ T cells, cytotoxic T cells and T helper cells. Ageing was also associated negatively with CMV-, influenza- and MART-1-specific naive and CD8+ T cells. There were significant increases in plasma monocyte chemotactic protein 1 (MCP-1) (CCL1) and regulated upon activation normal T cell expressed and secreted (RANTES) (CCL5) with age. We observed differences in cytokine profiles between males and females; specifically, women had higher levels of sCD40L and PDGF-AA. In summary, we demonstrated in healthy blood donors that ageing was associated with an increase in cellular Th2 bias and a decline in total numbers of T cells. Additionally, there was an increase in MCP-1 and RANTES with ageing. Women had higher levels of sCD40L and PDGF-AA than men.
The Dynamic Human Immune Response to Cancer: it Might Just be Rocket Science
Holtan, Shernan G. , Dronca, Roxana , Nevala, Wendy K. , Porrata, Luis F. , Mansfield, Aaron S. , Block, Matthew S. , Leontovich, Alexey A. , Grotz, Travis E. , Turner, James D. , Frisch, H. P., Markovic, Svetomir N. , Mansfield, Aaron S , Grotz, Travis E , Holtan, Shernan

Immunotherapy | September 13, 2011 | Volume: 3 | Issue: 9 | Pages: 1021-1024

10.2217/imt.11.109 Get It

Resectable pancreatic small cell carcinoma
Narang, Amol , Mansfield, Aaron S. , Herman, Joseph M. , Cameron, John L., Laheru, Dan, Eckhauser, Fred E., Olson, Mathew T., Hruban, Ralph H. , Miller, Robert C. , Andersen, Dana K. , Winter, Jordan Michael , Mansfield, Aaron S

Rare Tumors | January 28, 2011 | Volume: 3 | Issue: 1 | Pages: 13-17

10.4081/rt.2011.e5 Get It

Primary pancreatic small cell carcinoma (SCC) is rare, with just over 30 cases reported in the literature. Only 7 of these patients underwent surgical resection with a median survival of 6 months. Prognosis of SCC is therefore considered to be poor, and the role of adjuvant therapy is uncertain. Here we report two institutions’ experience with resectable pancreatic SCC. Six patients with pancreatic SCC treated at the Johns Hopkins Hospital (4 patients) and the Mayo Clinic (2 patients) were identified from prospectively collected pancreatic cancer databases and re-reviewed by pathology. All six patients underwent a pancreaticoduodenectomy. Clinicopathologic data were analyzed, and the literature on pancreatic SCC was reviewed. Median age at diagnosis was 50 years (range 27–60). All six tumors arose in the head of the pancreas. Median tumor size was 3 cm, and all cases had positive lymph nodes except for one patient who only had five nodes sampled. There were no perioperative deaths and three patients had at least one postoperative complication. All six patients received adjuvant therapy, five of whom were given combined modality treatment with radiation, cisplatin, and etoposide. Median survival was 20 months with a range of 9–173 months. The patient who lived for 9 months received chemotherapy only, while the patient who lived for 173 months was given chemoradiation with cisplatin and etoposide and represents the longest reported survival time from pancreatic SCC to date. Pancreatic SCC is an extremely rare form of cancer with a poor prognosis. Patients in this surgical series showed favorable survival rates when compared to prior reports of both resected and unresectable SCC. Cisplatin and etoposide appears to be the preferred chemotherapy regimen, although its efficacy remains uncertain, as does the role of combined modality treatment with radiation.
Angiomatoid fibrous histiocytoma in a 25-year-old male
Mansfield, Aaron S. , Larson, Brenda, Stafford, Scott L., Shives, Thomas C., Haddock, Michael G. , Dingli, David , Mansfield, Aaron S , Dingli, David

Rare Tumors | June 8, 2010 | Volume: 2 | Issue: 2 | Pages: 54-56

10.4081/rt.2010.e20 Get It

Angiomatoid fibrous histiocytoma (AFH) is a rare disease that is often misdiagnosed initially. Patients can present with a clinical picture concerning for other diseases, and pathologic review is not always revealing. Molecular diagnostics are increasingly being utilized to detect gene fusions characteristic for AFH. Surgery remains the mainstay of management, and can effectively control local recurrences and metastases. Herein we describe a case report of a 25-year-old gentleman whose presentation was concerning for lymphoma. Subsequently we review of the relevant literature.
Novel Therapeutics for The Treatment of Metastatic Melanoma
Mansfield, Aaron S. , Markovic, Svetomir N. , Mansfield, Aaron S

Future Oncology | May 19, 2009 | Volume: 5 | Issue: 4 | Pages: 543-557

10.2217/fon.09.15 Get It